Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Shares of Soleno Therapeutics, Inc. (“Soleno”) fell over 12% on September 10, 2025, after the company disclosed a patient death involving its treatment for Prader-Willi Syndrome, VYKAT XR. Previously, on Friday, August 15, 2025, Soleno stock dropped more than 8% after Scorpion Capital released a report alleging that VYKAT XR poses serious safety concerns and is potentially at risk of being withdrawn from the market. Gibbs Mura is investigating a potential Soleno Therapeutics, Inc. (NASDAQ: SLNO) Securities Class Action Lawsuit concerning whether Soleno has violated federal securities laws by providing false or misleading statements to investors.

IF YOU INVESTED IN SLNO, VISIT OUR SOLENO LAWSUIT INVESTIGATION WEBPAGE OR CALL US AT (888) 410-2925 TO GET MORE INFORMATION ABOUT HOW YOU MAY BE ABLE TO RECOVER YOUR LOSSES.

What is the Soleno Lawsuit Investigation About?

On August 15, 2025, Scorpion Capital released a 415-page report alleging that Soleno’s recently approved treatment for Prader-Willi syndrome, VYKAT XR, poses serious safety concerns and is potentially at risk of being withdrawn from the market. The report cites a “rapid pile-up of reports of children hospitalized for potential heart failure in recent weeks, shortly after starting VYKAT XR.”

Additionally, Scorpion Capital claims that Soleno’s “hocus-pocus” launch metrics obscure the company’s dependence on a controversial Florida physician that has a “pattern of association with questionable [Prader-Willi Syndrome] therapies.”

Finally, Scorpion Capital claims that “Soleno’s clinical trials were a sham that make a mockery of the scientific method,” specifically citing a withdrawal study that “exhibits red flags for suspect data/results,” along with comments from ex-employees and others expressing concern about the company’s alleged trial practices.

Following the report, shares of Soleno fell over 8% on August 15, 2025, causing harm to investors.

Then, on September 10, 2025, Soleno disclosed a patient death involving its Prader-Will Syndrome treatment, VYKAT XR, which was reported in the FDA’s Adverse Event Reporting System. Following this news, shares of Soleno fell over 12% on September 10, 2025, causing further harm to investors.

About Gibbs Mura, A Law Group

Gibbs Mura represents investors nationwide in securities litigation. The firm has recovered over a billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.